Please use this identifier to cite or link to this item:
doi:10.22028/D291-34585
Title: | Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy |
Author(s): | Khreish, Fadi Wiessner, Mona Rosar, Florian Ghazal, Zaidoon Sabet, Amir Maus, Stephan Linxweiler, Johannes Bartholomä, Mark Ezziddin, Samer |
Language: | English |
Title: | Biomolecules |
Volume: | 11 |
Issue: | 8 |
Publisher/Platform: | MDPI |
Year of Publication: | 2021 |
Free key words: | metastatic castration-resistant prostate cancer (mCRPC) Lutetium-177 PSMA-617 radioligand therapy 68Ga-PSMA-11 PET/CT molecular imaging-based response assessment tumor-toliver ratio (TLR) |
DDC notations: | 610 Medicine and health |
Publikation type: | Journal Article |
Abstract: | At present, little is known about the molecular imaging-based response assessment of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lutetium (177LuPSMA-617 RLT) in metastatic castration-resistant prostate cancer (mCRPC). Our study evaluated the response to RLT using both molecular imaging and biochemical response assessments, and their potential prediction of progression-free survival (PFS). Fifty-one consecutive patients given two cycles of RLT at 6-week intervals were analyzed retrospectively. 68Ga-PSMA-11 PET/CT was obtained about 2 weeks prior to the first and 4–6 weeks after the second cycle. Molecular imaging-based response using SUVpeak and tumor-to-liver ratio (TLR) was determined by modified PERCIST criteria. ∆TLR and ∆SUV were significantly correlated with ∆PSA (p < 0.001, each). After a median follow-up of 49 months, the median PFS (95% CI) was 8.0 (5.9–10.1) months. In univariate analysis, responders showing partial remission (PRPSA and PRTLR) had significantly (p < 0.001, each) longer PFS (median: 10.5 and 9.3 months) than non-responders showing either stable or progressive disease (median: 4.0 and 3.5 months). Response assessment using SUVpeak failed to predict survival. In multivariable analysis, response assessment using TLR was independently associated with PFS (p < 0.001), as was good performance status (p = 0.002). Molecular imaging-based response assessment with 68Ga-PSMA11 PET/CT using normalization of the total lesion PSMA over healthy liver tissue uptake (TLR) could be an appropriate biomarker to monitor RLT in mCRPC patients and to predict progression-free survival (PFS) of this treatment modality |
DOI of the first publication: | 10.3390/biom11081099 |
Link to this record: | urn:nbn:de:bsz:291--ds-345854 hdl:20.500.11880/31658 http://dx.doi.org/10.22028/D291-34585 |
ISSN: | 2218-273X |
Date of registration: | 27-Aug-2021 |
Faculty: | M - Medizinische Fakultät |
Department: | M - Radiologie M - Urologie und Kinderurologie |
Professorship: | M - Prof. Dr. Samer Ezziddin M - Keiner Professur zugeordnet |
Collections: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Files for this record:
File | Description | Size | Format | |
---|---|---|---|---|
biomolecules-11-01099.pdf | 3,65 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License